235 related articles for article (PubMed ID: 30301274)
1. Granulin A Synergizes with Cisplatin to Inhibit the Growth of Human Hepatocellular Carcinoma.
Qiao G; Xu H; Li C; Li X; Farooqi AA; Zhao Y; Liu X; Liu M; Stagos D; Lin X
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301274
[TBL] [Abstract][Full Text] [Related]
2. Interaction between granulin A and enolase 1 attenuates the migration and invasion of human hepatoma cells.
Chen X; Xu H; Wu N; Liu X; Qiao G; Su S; Tian Y; Yuan R; Li C; Liu X; Lin X
Oncotarget; 2017 May; 8(18):30305-30316. PubMed ID: 28415822
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells.
Dong X; Liu F; Li M
Anticancer Drugs; 2016 Apr; 27(4):286-99. PubMed ID: 26704389
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
5. Genistein reinforces the inhibitory effect of Cisplatin on liver cancer recurrence and metastasis after curative hepatectomy.
Chen P; Hu MD; Deng XF; Li B
Asian Pac J Cancer Prev; 2013; 14(2):759-64. PubMed ID: 23621233
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
7. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.
Ma B; Wang Y; Zhou X; Huang P; Zhang R; Liu T; Cui C; Liu X; Wang Y
J Cancer Res Clin Oncol; 2015 Mar; 141(3):419-29. PubMed ID: 25240826
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
9. Minocycline and cisplatin exert synergistic growth suppression on hepatocellular carcinoma by inducing S phase arrest and apoptosis.
Liu FY; Wu YH; Zhou SJ; Deng YL; Zhang ZY; Zhang EL; Huang ZY
Oncol Rep; 2014 Aug; 32(2):835-44. PubMed ID: 24919588
[TBL] [Abstract][Full Text] [Related]
10. [Role of enolase 1 in hepatocellular carcinoma and possible mechanism].
Yan TT; Ma LN; Luo X; Lu ZH; Liu Q; Xu YH; Liu XL; Ding XC
Zhonghua Gan Zang Bing Za Zhi; 2017 Jun; 25(6):429-434. PubMed ID: 28763860
[No Abstract] [Full Text] [Related]
11. Exosome-derived ENO1 regulates integrin α6β4 expression and promotes hepatocellular carcinoma growth and metastasis.
Jiang K; Dong C; Yin Z; Li R; Mao J; Wang C; Zhang J; Gao Z; Liang R; Wang Q; Wang L
Cell Death Dis; 2020 Nov; 11(11):972. PubMed ID: 33184263
[TBL] [Abstract][Full Text] [Related]
12. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
[No Abstract] [Full Text] [Related]
13. Ellagic acid synergistically potentiates inhibitory activities of chemotherapeutic agents to human hepatocellular carcinoma.
Zhong C; Qiu S; Li J; Shen J; Zu Y; Shi J; Sui G
Phytomedicine; 2019 Jun; 59():152921. PubMed ID: 31055231
[TBL] [Abstract][Full Text] [Related]
14. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic tigecycline enhances cisplatin activity against human hepatocellular carcinoma through inducing mitochondrial dysfunction and oxidative damage.
Tan J; Song M; Zhou M; Hu Y
Biochem Biophys Res Commun; 2017 Jan; 483(1):17-23. PubMed ID: 28069382
[TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
Zhang Y; Guan DX; Shi J; Gao H; Li JJ; Zhao JS; Qiu L; Liu J; Li N; Guo WX; Xue J; Zhou FG; Wu MC; Wang HY; Xie D; Cheng SQ
J Hepatol; 2013 Dec; 59(6):1255-63. PubMed ID: 23867314
[TBL] [Abstract][Full Text] [Related]
17. Smad3 Sensitizes Hepatocelluar Carcinoma Cells to Cisplatin by Repressing Phosphorylation of AKT.
Zhou HH; Chen L; Liang HF; Li GZ; Zhang BX; Chen XP
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110775
[TBL] [Abstract][Full Text] [Related]
18. BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin.
Zheng YH; Hu WJ; Chen BC; Grahn TH; Zhao YR; Bao HL; Zhu YF; Zhang QY
Liver Int; 2016 Dec; 36(12):1836-1847. PubMed ID: 27246112
[TBL] [Abstract][Full Text] [Related]
19. Antibody against granulin-epithelin precursor sensitizes hepatocellular carcinoma to chemotherapeutic agents.
Wong NC; Cheung PF; Yip CW; Chan KF; Ng IO; Fan ST; Cheung ST
Mol Cancer Ther; 2014 Dec; 13(12):3001-12. PubMed ID: 25253787
[TBL] [Abstract][Full Text] [Related]
20. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y
Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
